Press Releases

Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as...

Sandoz announced today that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche's Rituxan® / Mabthera), a leading monoclonal antibody indicated in conditions including non-Hodgkin's lymphoma and rheumatoid arthritis. The phase...

eyeforpharma recently interviewed: Hans Hoogkamer, Business and Science Affairs, Actelion Pharmaceuticals, Daniel Ghozzi, Managing Director CIS, UCB Pharma Russia & Rune Pilegaard  Associate Director, Business Support Nordics Sanofi-Aventis to see what they will be focusing on for the next...

Shire plc, the global specialty biopharmaceutical company, today announced results from a study of Vyvanse®, assessing its effect in a model for Excessive Daytime Sleepiness (EDS).  Vyvanse is a prescription medicine currently approved in the US, Canada and Brazil...

Merck KGaA announced that recruitment has been completed for the pivotal Phase III EXPAND(a) clinical trial investigating the efficacy of Erbitux® (cetuximab) in treating patients with advanced gastric cancer. The international study has recruited more than 870 patients since...

Bristol-Myers Squibb Company and AstraZeneca announced that KOMBIGLYZE XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States. ...

NovaBay Pharmaceuticals, a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay’s lead Aganocide, NVC-422 has shown in vitro activity against the...